ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2032

Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome

Kunal Chandwar1, Juhi Dixit1, Kriti Kishor1, DOGGA PRASANNA KUMAR2, DIGVIJAY EKBOTE3, PUNEET KUMAR1 and Urmila Dhakad1, 1King George's Medical University, Lucknow, India, 2KGMU, LUCKNOW, Uttar Pradesh, India, 3KING GEORGE MEDICAL UNIVERSITY, LUCKNOW, Uttar Pradesh, India

Meeting: ACR Convergence 2022

Keywords: Disease Activity, Imaging, Patient reported outcomes, Sjögren's syndrome, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: To assess major salivary gland involvement by ultrasonography and elastography in patients with Sjögren’s syndrome , compare it with controls and correlate the severity of ultrasonographic and elastographic involvement of major salivary gland with disease activity and quality of life.

Methods: In 35 pSS patients, disease activity was assessed by the European League Against Rheumatism (EULAR) Sjogren’s Syndrome Disease Activity Index (ESSDAI) and the EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI). The Salivary gland were assessed using the Hocevar and OMERACT score and Real time Elastography was performed for the salivary glands and were scored semiquantitatively.

Results: 35 patients of primary Sjögren’s Syndrome and 55 controls were included in the study. The patients were younger with a mean age (37.37±11.9). Mean USG scores were significantly higher (p < 0.001) in cases than controls including the Hocevar (13.94 ± 15.61 vs 0.80 ± 1.82), OMERACT (3.06 ± 3.59 vs 0.45 ± 0.978) and Elastography score (6.37 ± 2.850 vs 0.35 ± 0.584).

ESSDAI correlated with Hocevar Score (rho–0.801, p- < 0.001), OMERACT (rho – 0.793, p – < 0.001) and (rho – 0.538, p – < 0.001). ESSPRI correlated with Hocevar Score (rho-0.737, p -< 0.001), OMERACT score (rho – 0.702, p – < 0.001) and Elastography (rho – 0.388, p – < 0.001). The mean Hocevar Score was higher in patients with high disease activity (36.26 ± 8.05) compared to moderate disease activity (16.83 ± 15.59) and Low disease activity (4.62 ± 6.76). All the scores differentiated well between high and activity efficiently (p< 0.001), however for the OMERACT(p- 0.113) and Elastography score(p- 0.085) the difference between moderate and low disease activity was not Statistically significant. A multivariate linear regression analysis with Age, Gender, Duration of disease and disease activity parameter ESSDAI, ESSPRI was found to be significantly associated with USG scores. Logistic regression suggested A Hocevar score ≥ 17, OMERACT score≥ 2 and Elastography score ≥ 6 could predict a moderate or high disease activity significantly with an odds ratio of 49.3, 36 and 15 respectivly. Elastography score≥ 6 could predict a disease duration greater than 5 years significantly with an odds ratio of 8.5.

Conclusion: Both ultrasonographic and elastographic scores were higher in cases than controls. The Hocevar score had a very strong correlation with disease activity, patient reported outcomes and was able to differentiate between high, moderate, and low disease activity. The Elastography scores correlated with disease activity and duration of disease but were not as strong as the Ultrasound scores did. The OMERACT and elastography did not perform as well as Hocevar score did. There was a near-complete correlation of USG scores with Unilateral, Parotid and submandibular scores. The USG scores had a significant association with ESSDAI and ESSPRI in multivariable linear regression while Elastography had a significant association with ESSDAI and disease duration. A high USG score (Hocevar≥17 and an OMERACT score≥2) had a high likelihood of suggesting a high disease activity (ESSDAI≥5). Similarly, a high Elastography score (≥6) had a high likelihood of high disease activity and long disease duration.

Supporting image 1

Table 1: Baseline characteristics of patients in the study

Supporting image 2

Table 2: Comparison of USG and Elastography scores in Cases and controls

Supporting image 3

Table 3: Correlation, Multivariable linear regression and Logistic regression between ESSDAI and ESSPRI with USG scores and Elastography scores
ESSDAI: EULAR Sjögren’s syndrome disease activity index, ESSPRI: EULAR Sjögren’s syndrome patient reported index, OMERACT: Outcome Measures in Rheumatology Clinical trials
*-Multivariable linear regression analysis with Age, Gender, Duration of disease and disease activity parameter ESSDAI which included clinical domains and serological domains and patient-reported outcome ESSPRI as variables in the model.
$-Logistic regression was performed with the following parameters, ESSDAI  5 (moderate and high disease activity), Hocevar score >= 17, OMERACT score >= 2 in any gland and Elastography score >= 6


Disclosures: K. Chandwar, None; J. Dixit, None; K. Kishor, None; D. KUMAR, None; D. EKBOTE, None; P. KUMAR, None; U. Dhakad, None.

To cite this abstract in AMA style:

Chandwar K, Dixit J, Kishor K, KUMAR D, EKBOTE D, KUMAR P, Dhakad U. Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/major-salivary-gland-ultrasound-and-elastography-for-assessment-of-disease-activity-in-patients-of-primary-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/major-salivary-gland-ultrasound-and-elastography-for-assessment-of-disease-activity-in-patients-of-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology